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CommentaryThe Ryan White HIV/AIDS Program statute was first 
enacted into law in 1990 and was amended in 1996, 
2000, 2006, and 2009. More information about the leg-
islation and its history is available from the Health 
Resources and Services Administration (HRSA) HIV/
AIDS Bureau (HAB) at http://hab.hrsa.gov/about-
ryan-white-hivaids-program/ryan-white-hivaids-
program-legislation.
For the implementation of the Ryan White HIV/
AIDS Program (RWHAP) Metropolitan (Part A) and 
State (Part B) programs, HRSA HAB and the Centers 
for Disease Control and Prevention (CDC) collaborate 
to ensure the appropriate HIV and AIDS surveillance 
data are used in determining eligibility and funding 
allocation amounts. In FY 2017, HRSA used total 
counts of persons living with diagnosed HIV infection 
non-AIDS and persons living with infection ever clas-
sified as AIDS to calculate funding allocation amounts 
for eligible jurisdictions.
The number of persons living with diagnosed HIV 
infection non-AIDS and the number of persons living 
with infection ever classified as AIDS are used to 
determine funding levels for RWHAP Parts A and B. 
For FY 2017, CDC provided HRSA with data files 
containing the total number of persons reported living 
with diagnosed HIV infection non-AIDS and the total 
number of persons living with infection ever classified 
as AIDS through calendar year 2015 for all jurisdic-
tions. The number of persons living with diagnosed 
HIV infection non-AIDS and the number of persons 
living with infection ever classified as AIDS were 
added together to arrive at the total number of persons 
living with diagnosed HIV infection non-AIDS and 
infection ever classified as AIDS for each eligible 
area: eligible metropolitan area (EMA), transitional 
grant area (TGA), emerging community (EC), state, 
and territory. These totals were used in the RWHAP 
Parts A and B funding formula calculations. 
RWHAP PART A FUNDING 
For the RWHAP Part A funding formula, HRSA con-
tinues to use cumulative cases of AIDS reported to and 
confirmed by the Director of CDC for the most recent 
5 calendar years for which such data are available to HIV Surveillance Supplemental Report 5determine eligibility, as instructed by the RWHAP 
statute. RWHAP Part A has 2 categories of grantees: 
EMAs and TGAs. EMAs are defined as jurisdictions 
that have a cumulative total of more than 2,000 AIDS 
cases reported to and confirmed by the Director of 
CDC during the most recent 5 calendar years for 
which such data are available and a minimum popula-
tion of 50,000 persons. An area will continue to be an 
EMA unless it fails to meet both of the following 
requirements for 3 consecutive fiscal years: (a) a 
cumulative total of 2,000 or more AIDS cases 
reported to and confirmed by the Director of CDC 
during the most recent period of 5 calendar years for 
which such data are available, and (b) a cumulative 
total of 3,000 or more persons living with HIV infec-
tion ever classified as AIDS reported to and confirmed 
by the Director of CDC as of December 31 of the most 
recent calendar year for which such data are available. 
In FY 2017, there were 24 EMAs.
The other category of Part A grantees, TGAs, are 
defined as those jurisdictions that have a cumulative 
total of at least 1,000 but fewer than 2,000 AIDS cases 
reported to and confirmed by the Director of CDC 
during the most recent 5 calendar years for which such 
data are available and a minimum population of 
50,000 persons. An area will remain a TGA unless it 
fails to meet both of the following requirements for 3 
consecutive fiscal years: (a) a cumulative total of at 
least 1,000 but fewer than 2,000 AIDS cases reported 
to and confirmed by the Director of CDC during the 
most recent period of 5 calendar years for which such 
data are available, and (b) a cumulative total of 1,500 
or more persons living with HIV infection ever 
classified as AIDS reported to and confirmed by the 
Director of CDC as of December 31 of the most recent 
calendar year for which such data are available. 
Provisions in the RWHAP statute provided for a mod-
ification beginning in FY 2009: in the case where a 
metropolitan area has a cumulative total of at least 
1,400 but fewer than 1,500 persons living with HIV 
infection ever classified as AIDS as of December 31 of 
the most recent calendar year for which such data are 
available, such area shall be treated as having met  
criterion (b) as long as the area did not have more than 
5% unobligated balance as of the most recent fiscal  Vol. 22, No. 5
year for which such data are available. Areas that have 
fallen below either or both of the required TGA thresh-
olds, but that continue to be eligible per the RWHAP 
statute because they must fail both criteria for three 
consecutive years remain designated as TGAs and are 
presented in the TGA tables. For FY 2017, there were 
28 TGAs. 
The geographic boundaries for all jurisdictions that 
received Part A funding in FY 2017—both EMAs and 
TGAs—are those metropolitan statistical area (MSA) 
boundaries determined by the Office of Management 
and Budget (OMB) for use in federal statistical activi-
ties that were in effect when they were initially funded 
under Part A [1–3]. For all newly eligible areas, of 
which there were none in FY 2017, the boundaries are 
based on current MSA boundary definitions deter-
mined by OMB [1–3].
Minority AIDS Initiative (MAI) formula funds for 
Part A are awarded based on the reported number of 
minority persons living with diagnosed HIV infection 
non-AIDS and infection ever classified as AIDS 
reported through the end of the most recent calendar 
year as confirmed by the Director of CDC. Data for 
MAI formula funds are not included in this report. 
RWHAP PART B FUNDING 
RWHAP Part B and AIDS Drug Assistance Program 
(ADAP) funds are awarded via 3 separate grant award 
processes: the RWHAP Part B Formula award, the 
RWHAP Part B Supplemental award, and the RWHAP 
Part B ADAP Emergency Relief Fund (ERF) award. 
Each award is applied for and awarded separately. 
Funding is determined through formula and through 
demonstrated need, depending on the RWHAP Part B 
grant, as described below. The primary RWHAP Part 
B Formula award includes several components: the 
RWHAP Part B Base award, the ADAP Base award, 
the MAI award (for eligible states), the ECs award (for 
eligible states), and the ADAP Supplemental award 
(for those states that HRSA deems eligible and that 
choose to apply). The Part B Supplemental grant is a 
competitive award for states that demonstrate the need 
for additional Part B funds. ADAP ERF grants are 
competitive awards to help states prevent, reduce, or 
eliminate ADAP waiting lists and/or to implement 
ADAP-related cost-containment measures.
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SUPPLEMENTAL GRANTS
RWHAP Part B Base, ADAP Base, and EC funds are 
distributed using a funding formula process. The 
RWHAP Part B Base, ADAP Base, and EC formula 
awards are based on the reported number of persons 
living with diagnosed HIV infection non-AIDS and 
infection ever classified as AIDS in the state or terri-
tory through the end of the most recent calendar year 
as confirmed by the Director of CDC. The RWHAP 
Part B Base formula is a weighted relative distribution 
that also takes into account RWHAP Part A funding. 
Similarly, for recipients applying for MAI formula 
funds, awards are based on the reported number of 
racial/ethnic minorities living with diagnosed HIV 
infection non-AIDS and infection ever classified as 
AIDS reported through the end of the most recent cal-
endar year as confirmed by the Director of CDC. Data 
for MAI formula funds are not included in this report. 
Supplemental ADAP grants are awarded by the same 
formula as ADAP Base to states that meet any of the 
criteria listed in that section of the Funding Opportu-
nity Announcement for the purpose of providing med-
ications or insurance assistance for persons living with 
HIV infection. 
RWHAP Part B Supplemental, ADAP Supple-
mental, and ADAP ERF grants are awarded to states 
demonstrating the severity of the burden of HIV 
infection and the need for additional federal assis-
tance. The funds are intended to supplement the 
services otherwise provided by the state. The applica-
tions are reviewed through a federally approved 
technical review process. States and territories apply-
ing for supplemental funds must provide quantifiable 
data on HIV epidemiology, comorbidities, cost of 
care, the service needs of emerging populations, unmet 
need for core medical services, and unique service 
delivery challenges. 
RWHAP Part B EC eligibility is also determined 
based on the number of persons living with HIV 
infection ever classified as AIDS in that jurisdiction. 
ECs are defined as metropolitan areas for which there 
have been at least 500 but fewer than 1,000 AIDS 
cases reported to and confirmed by the Director of 
CDC during the most recent 5 calendar years for 
which such data are available. An area will remain an 
EC unless it fails to meet both of the following 
requirements for 3 consecutive fiscal years: (a) a 
cumulative total of at least 500 but fewer  Vol. 22, No. 5
than 1,000 cases of AIDS reported to and confirmed by 
the Director of CDC during the most recent period of 
5 calendar years for which such data are available, and 
(b) a cumulative total of 750 or more persons living
with HIV infection ever classified as AIDS reported to
and confirmed by the Director of CDC as of December
31 of the most recent year for which such data are
available. As with EMAs and TGAs, the geographic
boundaries for ECs are those that were determined by
OMB and that were in effect when initially funded.
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Technical NotesIn October 2009, Congress enacted amendments to the 
Ryan White HIV/AIDS Program (RWHAP) statute. 
The Act specifies the use of surveillance data on per-
sons living with diagnosed HIV infection non-AIDS 
and infection ever classified as AIDS to determine 
formula funding for RWHAP Parts A and B HIV care 
and services programs. RWHAP authorizes the 
Centers for Disease Control and Prevention (CDC) to 
provide HIV non-AIDS and AIDS case surveillance 
data to the Health Resources and Services Admin-
istration (HRSA) for use in their funding formula for 
all jurisdictions. 
As of December 2015, CDC was not accepting HIV 
case data from the Marshall Islands and the Federated 
States of Micronesia as their surveillance systems had 
not yet been certified. However, in the event that 
another jurisdiction reported cases that were diag-
nosed in either the Marshall Islands or the Federated 
States of Micronesia, the cases would be reflected in 
the data that CDC sends to HRSA annually. 
DATA REQUIREMENTS AND DEFINITIONS
Case counts in all tables are presented by residence at 
earliest HIV diagnosis for persons with diagnosed HIV 
infection non-AIDS and residence at earliest AIDS 
diagnosis for persons with infection ever classified as 
AIDS. Data are presented by date of report rather than 
date of diagnosis (e.g., reported AIDS cases in the last 
5 years). Boundaries for eligible metropolitan areas 
(EMAs) and transitional grant areas (TGAs) that 
became eligible prior to FY 2007 are based on the 
Office of Management and Budget (OMB) metropoli-
tan statistical area delineations that were in effect for 
such areas for FY 1994 (additional information on his-
torical delineations is available at http://www 
.census.gov/geographies/reference-files/time-series/
demo/metro-micro/historical-delineation-files.html). 
Boundaries for EMAs, TGAs, and emerging 
communities (ECs) that became eligible after 2006 
are determined using applicable OMB definitions 
based on the year of first eligibility.
Reported persons living with diagnosed HIV infec-
tion non-AIDS or infection ever classified as AIDS are 
defined as persons reported as “alive” at last update. 
HIV Surveillance Supplemental Report 8HIV non-AIDS cases and AIDS case data reported 
from CDC met the CDC surveillance case definitions 
published in the 2008 revised surveillance case defini-
tions for HIV infection among adults, adolescents, and 
children <18 months and for HIV infection and AIDS 
among children aged 18 months to <13 years [4]. Vol. 22, No. 5
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Table 1. Reported AIDS cases and persons reported living with diagnosed HIV infection ever 
classified as AIDS, by area of residence, 2011–2015 and as of December 2015—eligible 
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program  
Reported AIDS cases
2011–2015
Persons reported living with 
diagnosed HIV infection ever 
classified as AIDS (as of 
December 2015)
Area of residence No. No.
Eligible metropolitan areas (EMAs)
Atlanta–Sandy Springs–Marietta, Georgia 6,688 15,734
Baltimore, Maryland 2,572 10,125
Boston–Brockton–Nashua, Massachusetts–New Hampshire 2,358 9,805
Chicago, Illinois 4,260 16,230
Dallas, Texas 3,026 10,517
Detroit, Michigan 1,510 5,547
Fort Lauderdale, Florida 2,134 9,570
Houston, Texas 4,359 14,325
Los Angeles–Long Beach, California 5,690 27,712
Miami, Florida 3,114 14,751
Nassau–Suffolk, New York 881 3,667
New Haven–Bridgeport–Danbury–Waterbury, Connecticut 660 4,069
New Orleans, Louisiana 1,241 4,583
New York, New York 10,041 64,476
Newark, New Jersey 1,627 7,193
Orlando, Florida 1,651 5,918
Philadelphia, Pennsylvania–New Jersey 3,382 14,034
Phoenix–Mesa, Arizona 1,228 5,025
San Diego, California 1,285 7,489
San Francisco, California 1,339 11,008
San Juan–Bayamon, Puerto Rico 1,407 6,643
Tampa–St. Petersburg–Clearwater, Florida 1,768 6,510
Washington, DC–Maryland–Virginia–West Virginia 4,420 19,184
West Palm Beach–Boca Raton, Florida 1,039 5,050
Transitional grant areas (TGAs)
Austin–San Marcos, Texas 763 3,065
Baton Rouge, Louisiana 953 2,670
Bergen–Passaic, New Jersey 535 2,477
Charlotte–Gastonia–Concord, North Carolina–South Carolina 1,264 2,924
Cleveland–Lorain–Elyria, Ohio 488 2,480
Columbus, Ohio 798 2,348
Denver, Colorado 743 3,964
Fort Worth–Arlington, Texas 962 2,682
Hartford, Connecticut 387 2,372
Indianapolis, Indiana 693 2,542
Jacksonville, Florida 1,090 3,823
Jersey City, New Jersey 661 2,950
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Note. See Commentary for definition of eligible metropolitan areas (EMAs) and transitional grant areas (TGAs).
Kansas City, Missouri–Kansas 600 2,782
Las Vegas, Nevada–Arizona 1,033 3,463
Memphis, Tennessee–Mississippi–Arkansas 1,432 3,746
Middlesex–Somerset–Hunterdon, New Jersey 336 1,670
Minneapolis–St. Paul, Minnesota–Wisconsin 736 3,062
Nashville–Davidson–Murfreesboro, Tennessee 593 2,646
Norfolk–Virginia Beach–Newport News, Virginia 846 2,729
Oakland, California 1,056 5,225
Orange County, California 767 4,048
Portland–Vancouver, Oregon–Washington 584 2,752
Riverside–San Bernardino, California 1,275 5,354
Sacramento, California 507 2,134
St. Louis, Missouri–Illinois 851 3,587
San Antonio, Texas 937 3,199
San Jose, California 422 2,324
Seattle–Bellevue–Everett, Washington 781 4,507
Table 1. Reported AIDS cases and persons reported living with diagnosed HIV infection ever 
classified as AIDS, by area of residence, 2011–2015 and as of December 2015—eligible 
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program (cont)
Reported AIDS cases
2011–2015
Persons reported living with 
diagnosed HIV infection ever 
classified as AIDS (as of 
December 2015)
Area of residence No. No.
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Note. See Commentary for definition of emerging communities (ECs).
* This MSA was formerly named Bradenton–Sarasota–Venice, Florida, but the counties delineating the metropolitan statistical areahave not changed.
Table 2. Reported AIDS cases and persons reported living with diagnosed HIV infection ever 
classified as AIDS, by area of residence, 2011–2015 and as of December 2015—emerging 
communities for the Ryan White HIV/AIDS Program  
Reported AIDS cases
2011–2015
Persons reported 
living with diagnosed 
HIV infection ever 
classified as AIDS (as of 
December 2015)
Emerging communities (ECs) No. No.
Albany–Schenectady–Troy, New York 259 1,174
Augusta–Richmond County, Georgia–South Carolina 498 1,036
Bakersfield, California 254 1,220
Birmingham–Hoover, Alabama 580 1,516
Buffalo–Niagara Falls, New York 390 1,298
Charleston–North Charleston, South Carolina 376 1,320
Cincinnati–Middletown, Ohio–Kentucky–Indiana 535 1,955
Columbia, South Carolina 577 2,412
Jackson, Mississippi 531 1,660
Lakeland, Florida 335 1,164
Louisville, Kentucky–Indiana 485 1,612
Milwaukee–Waukesha–West Allis, Wisconsin 385 1,553
North Port–Bradenton–Sarasota, Florida* 226 1,070
Oklahoma City, Oklahoma 434 1,303
Philadelphia, Pennsylvania–New Jersey–Delaware–Maryland—
Wilmington Division
306 1,489
Pittsburgh, Pennsylvania 424 1,788
Port St. Lucie–Fort Pierce, Florida 374 1,451
Providence–New Bedford–Fall River, Rhode Island–Massachusetts 323 1,475
Raleigh–Cary, North Carolina 448 1,761
Richmond, Virginia 605 2,057
Rochester, New York 359 1,671
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Table 3. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever 
classified as AIDS, and total, by area of residence, as of December 2015—United States and 
dependent areas for the Ryan White HIV/AIDS Program  
HIV non-AIDS
HIV infection 
ever classified 
as AIDS Total
Area of residence No. No. No.
Alabama 7,044 5,363 12,407
Alaska 304 395 699
Arizona 7,470 6,789 14,259
Arkansas 2,846 2,530 5,376
California 52,497 74,205 126,702
Colorado 6,593 5,276 11,869
Connecticut 3,831 7,059 10,890
Delaware 1,238 1,993 3,231
District of Columbia 6,783 9,099 15,882
Florida 49,233 59,341 108,574
Georgia 20,074 23,334 43,408
Hawaii 1,080 1,481 2,561
Idaho 460 442 902
Illinois 17,391 19,044 36,435
Indiana 5,069 5,275 10,344
Iowa 947 1,261 2,208
Kansas 1,411 1,654 3,065
Kentucky 3,145 3,258 6,403
Louisiana 9,884 10,790 20,674
Maine 588 664 1,252
Maryland 14,606 17,389 31,995
Massachusetts 8,143 10,958 19,101
Michigan 7,725 8,323 16,048
Minnesota 4,178 3,529 7,707
Mississippi 4,958 4,598 9,556
Missouri 5,901 6,485 12,386
Montana 179 251 430
Nebraska 925 1,070 1,995
Nevada 4,123 3,927 8,050
New Hampshire 552 634 1,186
New Jersey 17,563 19,619 37,182
New Mexico 1,292 1,658 2,950
New York 53,749 78,531 132,280
North Carolina 16,259 12,283 28,542
North Dakota 141 122 263
Ohio 10,897 9,774 20,671
Oklahoma 3,008 2,700 5,708
Oregon 2,362 3,483 5,845
Pennsylvania 14,965 19,309 34,274
Rhode Island 851 1,502 2,353
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Note. The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2017 funding calculations.
* See Technical Notes regarding data reported for these jurisdictions.
South Carolina 7,465 8,881 16,346
South Dakota 296 215 511
Tennessee 8,612 8,784 17,396
Texas 37,681 43,613 81,294
Utah 1,213 1,489 2,702
Vermont 227 274 501
Virginia 12,167 10,490 22,657
Washington 5,534 6,695 12,229
West Virginia 824 953 1,777
Wisconsin 2,887 2,819 5,706
Wyoming 135 158 293
American Samoa 0 1 1
Federated States of Micronesia* 0 0 0
Guam 41 34 75
Marshall Islands* 0 1 1
Northern Mariana Islands 0 2 2
Palau 3 1 4
Puerto Rico 8,238 10,739 18,977
U.S. Virgin Islands 264 350 614
Table 3. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever 
classified as AIDS, and total, by area of residence, as of December 2015—United States and 
dependent areas for the Ryan White HIV/AIDS Program (cont)
HIV non-AIDS
HIV infection 
ever classified 
as AIDS Total
Area of residence No. No. No.
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Table 4. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever 
classified as AIDS, and total, by area of residence, as of December 2015—eligible 
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program 
HIV non-AIDS
HIV infection ever 
classified as AIDS Total
Area of residence No. No. No.
Eligible metropolitan areas (EMAs)
Atlanta–Sandy Springs–Marietta, Georgia 12,998 15,734 28,732
Baltimore, Maryland 8,242 10,125 18,367
Boston–Brockton–Nashua, Massachusetts–New Hampshire 7,191 9,805 16,996
Chicago, Illinois 14,779 16,230 31,009
Dallas, Texas 9,353 10,517 19,870
Detroit, Michigan 4,972 5,547 10,519
Fort Lauderdale, Florida 8,617 9,570 18,187
Houston, Texas 11,980 14,325 26,305
Los Angeles–Long Beach, California 21,599 27,712 49,311
Miami, Florida 14,244 14,751 28,995
Nassau–Suffolk, New York 2,600 3,667 6,267
New Haven–Bridgeport–Danbury–Waterbury, Connecticut 2,172 4,069 6,241
New Orleans, Louisiana 4,040 4,583 8,623
New York, New York 43,397 64,476 107,873
Newark, New Jersey 6,596 7,193 13,789
Orlando, Florida 5,454 5,918 11,372
Philadelphia, Pennsylvania–New Jersey 10,996 14,034 25,030
Phoenix–Mesa, Arizona 5,810 5,025 10,835
San Diego, California 5,786 7,489 13,275
San Francisco, California 6,878 11,008 17,886
San Juan–Bayamon, Puerto Rico 5,486 6,643 12,129
Tampa–St. Petersburg–Clearwater, Florida 5,176 6,510 11,686
Washington, DC–Maryland–Virginia–West Virginia 16,065 19,184 35,249
West Palm Beach–Boca Raton, Florida 3,283 5,050 8,333
Transitional grant areas (TGAs)
Austin–San Marcos, Texas 2,503 3,065 5,568
Baton Rouge, Louisiana 2,405 2,670 5,075
Bergen–Passaic, New Jersey 2,085 2,477 4,562
Charlotte–Gastonia–Concord, North Carolina–South Carolina 4,108 2,924 7,032
Cleveland–Lorain–Elyria, Ohio 2,817 2,480 5,297
Columbus, Ohio 3,043 2,348 5,391
Denver, Colorado 5,168 3,964 9,132
Fort Worth–Arlington, Texas 2,471 2,682 5,153
Hartford, Connecticut 1,282 2,372 3,654
Indianapolis, Indiana 2,425 2,542 4,967
Jacksonville, Florida 2,898 3,823 6,721
Jersey City, New Jersey 2,639 2,950 5,589
Kansas City, Missouri–Kansas 2,157 2,782 4,939
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Note. See Commentary for definition of eligible metropolitan areas (EMAs) and transitional grant areas (TGAs).
The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2017 funding calculations.
Las Vegas, Nevada–Arizona 3,642 3,463 7,105
Memphis, Tennessee–Mississippi–Arkansas 3,968 3,746 7,714
Middlesex–Somerset–Hunterdon, New Jersey 1,432 1,670 3,102
Minneapolis–St. Paul, Minnesota–Wisconsin 3,700 3,062 6,762
Nashville–Davidson–Murfreesboro, Tennessee 2,636 2,646 5,282
Norfolk–Virginia Beach–Newport News, Virginia 3,942 2,729 6,671
Oakland, California 2,847 5,225 8,072
Orange County, California 3,210 4,048 7,258
Portland–Vancouver, Oregon–Washington 2,043 2,752 4,795
Riverside–San Bernardino, California 3,631 5,354 8,985
Sacramento, California 1,739 2,134 3,873
St. Louis, Missouri–Illinois 3,595 3,587 7,182
San Antonio, Texas 2,767 3,199 5,966
San Jose, California 1,213 2,324 3,537
Seattle–Bellevue–Everett, Washington 3,836 4,507 8,343
Table 4. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever 
classified as AIDS, and total, by area of residence, as of December 2015—eligible 
metropolitan areas and transitional grant areas for the Ryan White HIV/AIDS Program (cont)
HIV non-AIDS
HIV infection ever 
classified as AIDS Total
Area of residence No. No. No.
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Note. See Commentary for definition of emerging communities (ECs).
The number of cases shown in the Total column was used by the Health Resources and Services Administration in FY 2017 funding calculations.
* This MSA was formerly named Bradenton–Sarasota–Venice, Florida, but the counties delineating the metropolitan statistical area
have not changed.
Table 5. Reported number of persons living with diagnosed HIV infection non-AIDS, infection ever 
classified as AIDS, and total, by area of residence, as of December 2015—emerging 
communities for the Ryan White HIV/AIDS Program  
HIV non-AIDS
HIV infection ever 
classified as AIDS Total
Emerging communities (ECs) No. No. No.
Albany–Schenectady–Troy, New York 915 1,174 2,089
Augusta–Richmond County, Georgia–South Carolina 1,020 1,036 2,056
Bakersfield, California 789 1,220 2,009
Birmingham–Hoover, Alabama 2,271 1,516 3,787
Buffalo–Niagara Falls, New York 1,171 1,298 2,469
Charleston–North Charleston, South Carolina 1,185 1,320 2,505
Cincinnati–Middletown, Ohio–Kentucky–Indiana 2,007 1,955 3,962
Columbia, South Carolina 1,923 2,412 4,335
Jackson, Mississippi 1,781 1,660 3,441
Lakeland, Florida 823 1,164 1,987
Louisville, Kentucky–Indiana 1,696 1,612 3,308
Milwaukee–Waukesha–West Allis, Wisconsin 1,609 1,553 3,162
North Port–Bradenton–Sarasota, Florida* 768 1,070 1,838
Oklahoma City, Oklahoma 1,489 1,303 2,792
Philadelphia, Pennsylvania–New Jersey–Delaware–Maryland—
Wilmington Division
922 1,489 2,411
Pittsburgh, Pennsylvania 1,556 1,788 3,344
Port St. Lucie–Fort Pierce, Florida 622 1,451 2,073
Providence–New Bedford–Fall River, Rhode Island–
Massachusetts
829 1,475 2,304
Raleigh–Cary, North Carolina 1,935 1,761 3,696
Richmond, Virginia 2,615 2,057 4,672
Rochester, New York 1,321 1,671 2,992
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